Regardless, the clinical application of TIL therapy in mesothelioma faces substantial logistical challenges, including limited cell yields, complex expansion protocols, and reliance on IL-2 support, compounded by the low surgical eligibility rate of PM patients. This evidence concerns the gene IL2 and mesothelioma.